Role of HOXA1-4 in the development of genetic and malignant diseases

Abstract

The HOXA genes, belonging to the HOX family, encompass 11 members (HOXA1-11) and exert critical functions in early embryonic development, as well as various adult processes. Furthermore, dysregulation of HOXA genes is implicated in genetic diseases, heart disease, and various cancers. In this comprehensive overview, we primarily focused on the HOXA1-4 genes and their associated functions and diseases. Emphasis was placed on elucidating the impact of abnormal expression of these genes and highlighting their significance in maintaining optimal health and their involvement in the development of genetic and malignant diseases. Furthermore, we delved into their regulatory mechanisms, functional roles, and underlying biology and explored the therapeutic potential of targeting HOXA1-4 genes for the treatment of malignancies. Additionally, we explored the utility of HOXA1-4 genes as biomarkers for monitoring cancer recurrence and metastasis.

Introduction

Homeobox (HOX) genes are a group of evolutionarily conserved transcription factors, which can be categorized into four family clusters: HOXA, HOXB, HOXC, and HOXD (Fig. 1). These genes play crucial roles in cellular development and the establishment of body patterns during embryogenesis. For instance, mutations in HOXA13 have been associated with the absence of thumb formation [1]. Similarly, heterozygous alterations in HOXD13 are linked to Synpolydactyly 1, an inherited limb deformity [2]. Furthermore, HOX genes have been implicated in the progression of neurological disorders. Notably, the HOXD subset is critically involved in the development of monosynaptic sensory-motor connections. In mice, the loss of Hoxd9, Hoxd10, and Hoxd11 results in locomotion defects [3]. Moreover, the regulation of HOXB3 by LncRNA147410.3 influences crucial physiological processes, such as proliferation, differentiation, and apoptosis, in mouse microglia [4]. Dysregulated methylation levels affecting HOXB4, HOXC4, and HOXD1 have been associated with neural tube defects (NTDs) [5]. Additionally, abnormal expression patterns of HOX genes have been observed in various diseases, including hypertensive disorder complicating pregnancy (HDCP) [6] and allergic asthma [7]. For example, miR-1233 directly targets HOXB3, suppressing trophoblast cell invasion, and contributing to HDCP. Furthermore, HOX5 regulates the function of Th2 cells in chronic allergic inflammation by modulating Gata3.

Fig. 1

The human HOX gene clusters. 39 HOX are organized into four chromosomal clusters: HOXA, HOXB, HOXC, and HOXD

Previous research has revealed the regulatory role of HOX genes in human cancer development, affecting processes such as cell proliferation, differentiation, apoptosis, metastasis, angiogenesis, and epithelial-mesenchymal transition (EMT). While some HOX genes are reported to function as tumor suppressors, recent studies suggest that HOX genes primarily act as oncogenes in cancer progression. For example, HOXD1 is downregulated in kidney renal clear cell carcinoma (KIRC), and its high expression is associated with the inhibition of cancer cell proliferation, cell cycle progression, and TGF-β signaling [8]. Similarly, both loss-of-function and gain-of-function experiments have demonstrated that HOXD13 inhibits cell proliferation and migration in prostate cancer (PCa) by blocking BMP4/SMAD1 signaling [9]. Conversely, HOXB3/6/7/8/9 are highly expressed in lung adenocarcinoma (LUAD) and correlate with poor overall survival (OS) [10]. Additionally, HOXC6/8/9/10/11/13 are overexpressed in gastric cancer (GC) and are associated with an unfavorable prognosis [11]. Our previous research discovered that HOXD3 acted as an oncogene, promoting the proliferation, metastasis, invasion, and angiogenesis of liver cancer through the ITGA and EGFR pathways [12, 13].

HOXA genes, a specific subset within the HOX family, have received significant attention in the fields of organ development, disease pathogenesis, and various cancer types. These genes have been identified as crucial players in cancer progression, acting both as oncogenes and inhibitors. For instance, HOXA5 has been implicated in the regulation of vascular smooth muscle cell phenotype, thereby exerting a protective effect against carotid atherosclerosis [14]. In GC, co-expression of HOXA6 with PBX2 has been observed, resulting in enhanced cell proliferation, metastasis, and invasion [15]. However, conflicting findings suggest that HOXA6 actually acts as an inhibitor, suppressing cell proliferation through the PI3K/AKT signaling pathway in clear cell renal cell carcinoma [16].

Gaining a comprehensive understanding of the involvement of HOXA genes in the development of HOXA-related diseases is crucial for identifying novel treatment targets and innovative therapeutic strategies. Therefore, the objective of this study is to provide an extensive review encompassing the diverse functions of HOXA1-4 genes in the pathogenesis of both inherited and acquired diseases. This will be achieved through an evaluation of their regulatory mechanisms, biological functions, and associated pathways. Additionally, we aim to consolidate preliminary data that support the potential use of these genes as targets for gene therapy, offering new perspectives for the treatment of HOXA-related diseases.

Structural domains of HOXA1-4

Mammals possess a total of 39 HOX genes, which are organized into four chromosomal clusters: HOXA (7p15-p14), HOXB (17q21-q22), HOXC (12q12-q13), and HOXD (2q31-q32). These genes encode transcription factors that contain homeodomains and are vital for the development of vertebral architecture along the anteroposterior axis. Notably, the expression of HOX genes follows a specific pattern, with the front-end genes at the 3' end being expressed first. Consequently, they can activate the expression of the posterior HOX genes located at the 5' end. This sequential expression leads to temporal and spatial collinearity among the HOX genes within each cluster. Thus, the regulatory interactions among HOX genes during embryonic development ultimately determine the morphology of body segments.

The HOXA genes are arranged in a sequential manner based on their paralog groups, which span from 1 to 13. The HOXA gene cluster comprises HOXA1, HOXA2, HOXA3, HOXA4, HOXA5, HOXA6, HOXA7, HOXA9, HOXA10, HOXA11, and HOXA13. Remarkably, the genes HOXA1-4 significantly influence the development of the head in mammals (Fig. 1).

Different roles of HOXAs in common diseases

HOXA1

The crucial role played by HOXA genes in cell physiology is evident in the numerous diseases that arise as a result of gene mutations or altered expression (Fig. 2). For instance, mutations in HOXA1 have been linked to a group of genetic disorders referred to as "HOXA1-related syndromes" [17]. The phenotypic manifestations of these syndromes can vary across different populations. One of the examples is Bosley-Salih-Alorainy Syndrome [18], which has been reported predominantly among Middle Eastern patients. Characteristic symptoms of this syndrome include facial weakness, hearing impairment, sensorineural hearing loss, cardiac malformations, and developmental delays. Another illustration is Athabascan Brain Dysgenesis Syndrome (ABDS), observed primarily in the Native American population. Individuals affected by ABDS exhibit features such as mental retardation, central hypoventilation, facial weakness, and conotruncal heart defects [19, 20]. Additionally, a truncated mutation of HOXA1 has been identified in pigs with congenital malformation of the outer ears, discovered through RNA sequencing analysis of pig embryos. Given that the incidence rate of diseases in pigs is similar to that in humans, this finding can act as a reference point for comprehending the molecular mechanisms underlying genetic diseases in humans [21].

Fig.2

HOXA1-4 genes have participated in the regulation of gene expression related to the heart, blood vessels, viruses, genetic diseases, neurology, psychiatry, and developmental defects

In recent years, several studies have provided evidence of the involvement of HOXA1 expression in heart disease, particularly in congenital heart defects (CHD) [22]. For instance, investigations have revealed that variations in the poly-histidine repeat motif of HOXA1 can induce the development of bicuspid aortic valve (BAV) in mice and zebrafish [23]. BAV represents the most common form of CHD and is characterized clinically by various abnormalities in the aortic valve, including aortic stenosis and regurgitation, endocarditis, and ascending aortic aneurysm/dissection, affecting approximately one-third of patients. Furthermore, HOXA1 is expressed in precursors of cardiac neural crest cells (NCCs) and contributes to heart development through the regulation of NCCs [24].

HOXA1 not only plays a crucial role in heart disease regulation but is also involved in joint-related diseases, specifically through its influence on apoptosis. Increased levels of miR-10a-5p promote chondrocyte apoptosis by suppressing HOXA1 expression in osteoarthritis [25]. This finding has been further supported by miR-18a-3p, which targets the 3' UTR of HOXA1, thus inhibiting its expression and inducing chondrocyte apoptosis [26].

In studies pertaining to autism, researchers have discovered a correlation between the HOXA1 A218G polymorphism and variations in head circumference among autistic patients [27]. Additionally, Ingram et al. have determined that the presence of a (His)73(Arg) polymorphism (A:G) in the HOXA1 gene significantly contributes to the susceptibility of autism [28]. However, these findings have been called into question by the Dr. Devlin group, who conducted an analysis of genotype frequencies and allele transmissions using data from the Collaborative Programs of Excellence in Autism network. Their results suggest that the (His)73(Arg) polymorphism in the HOXA1 gene does not have a significant association with autism [29].

HOXA has demonstrated functional involvement in various diseases, such as endometriosis [30], hypoxic-ischemic brain damage (HIBD) [31], Hepatitis C virus (HCV), and sepsis-induced pneumonia [32]. In endometriosis, all HOXA and HOXB paralogs, except for HOXA1, exhibited significant down-regulation in ectopic tissues compared to control tissues. In the case of HIBD, the long non-coding RNA NEAT1 competes with miR-339-5p to effectively increase HOXA1 expression, promoting neuronal cell viability and suppressing apoptosis during hypoxia–ischemia. Similarly, in HCV research, the expression of HOXA transcript antisense RNA myeloid-specific 1 (HOTAIRM1) is upregulated, suggesting its potential as an immunomodulatory target that regulates the expressions of HOXA1 and miR-124 and promotes the expansion of myeloid-derived suppressor cells [33]. Correspondingly, miR-181c targets HOXA1 and, through the regulation of STAT3 and STAT5, hampers HCV replication [34]. Lastly, in sepsis-induced pneumonia, the decreased expression of urothelial carcinoma-associated 1 (UCA1) leads to the downregulation of EZH2, consequently increasing HOXA1 expression. This upregulation of HOXA1 contributes to the mitigation of sepsis-induced pneumonia progression.

HOXA2

Increasing evidence supports the involvement of epigenetic regulation in various diseases related to HOXA2. For example, a DNA methylation analysis revealed that HOXA2 exhibits hypomethylation in carotid atherosclerotic plaques, in contrast to intact tissues from internal mammary arteries and saphenous veins [35]. The impact of HOXA2 on fibrosis progression in chronic hepatitis B infection was confirmed using Illumina Infinium Bead Arrays. Findings from these studies indicate a significant association between hypermethylation of HOXA2 and severe fibrosis [36]. In the investigation of orofacial cleft, distinct methylation patterns were observed for different subtypes of orofacial cleft within the HOXA2 gene [37]. Additionally, the long non-coding RNA HOTAIRM1 was found to suppress DNMT1 enrichment on the HOXA2 promoter, resulting in hypomethylation and subsequent induction of HOXA2 expression, ultimately leading to osteogenesis of human periodontal ligament stem cells [38].

Furthermore, the expression of HOXA2 has been linked to ulcerative colitis (UC). HOXA2 was found to be significantly downregulated in UC patients compared to both remission patients and healthy controls [39]. Moreover, HOXA2 has also been associated with congenital malformations of the external ear. Utilizing Phenolyzer, a phenotypic-based gene analyzer, computational analysis has confirmed this relationship [40]. Supporting this finding, Si et al. discovered that HOXA2 expression is connected to the evolutionarily conserved enhancer region of the homeobox 1 transcription factor gene (HMX1), which plays a role in craniofacial structure development [41]. Additionally, HOXA2 is involved in the progression of chondrogenesis and has been implicated in human idiopathic proportionate short stature due to its dysregulation [42].

HOXA3

In wound healing, research has revealed that HOXA3 promotes neovascularization to expedite the wound healing. This effect is achieved by mobilizing, recruiting, and enhancing the differentiation of multipotent bone marrow-derived cells, while concurrently inhibiting the expression of proinflammatory nuclear factor kappa B pathway-related proteins [43]. Similarly to HOXA1, HOXA3 also plays a critical role in CHD development [22]. HOXA3 exhibits distinct expression patterns within sub-domains of second heart field cells, which contribute to embryonic heart development during cardiac looping [44]. The absence of the third arch artery, resulting in carotid artery system malformation, has been observed in homozygous HOXA3 mutants [45, 46]. Moreover, HOXA3 has been associated with epigenetic modifications. Differential hypermethylation in HOXA3 has been linked to neurodegeneration in late-onset Alzheimer's disease (AD) [47]. Interestingly, HOXA3 methylation has also been correlated with physical activity, as a study demonstrated that reduced physical activity in young adults is associated with an upregulation of HOXA3 methylation [48].

HOXA4

The expression of HOXA4 has been implicated in heart failure (HF). In patients with HF, the long noncoding RNA Myocardial Infarction-Associated Transcript (MIAT) exhibits upregulation, thereby enhancing the expression of HOXA4 through the suppression of miR-150. This contributes to the progression of HF [49]. Additionally, HOXA4 plays a crucial role in maintaining spatial identity within the adult aorta, and its upregulation can decrease susceptibility to human abdominal aortic aneurysms [50]. Likewise, studies conducted by Kimura et al. utilizing a HOXA4-deficient mouse model have shown that HOXA4 interacts with Transcriptional Enhancer Activator Domain (TEADs), leading to the attenuation of Yes-Associated Protein (YAP)/TEAD-mediated transcription by competing for TEAD binding. This interaction affects the phenotypic switching of vascular smooth muscle cells [51]. Furthermore, HOXA4 has the ability to induce the differentiation of human umbilical cord mesenchymal stem cells into epidermal-like cells, thereby promoting skin repair [52].

In the investigation of genetic-related diseases, abnormal expression of HOXA4 has been observed, with mutations in HOXA4 being associated with microtia-atresia, a rare congenital condition [53]. Additionally, HOXA4 is involved in epigenetic modifications. The expression of HOXA4 is inhibited by TASP1, a heterodimeric endopeptidase that activates histone methyltransferases of the KMT2 family. Loss-of-function variants of TASP1 can lead to Suleiman-El-Hattab syndrome (SULEHS), a disorder affecting histone modification [54]. Moreover, alterations in DNA methylation at cytosine-phosphate-guanine (CpG) sites within HOXA4 have been linked to both AD [55] and periodontitis [56]. The increased mRNA level of HOXA4 has also been correlated with hypospadias [57].

The information presented highlights the pivotal involvement of CpG methylation and gene mutations in the onset and progression of diseases influenced by HOXA genes. Additionally, the functions attributed to HOXA1-4 primarily revolve around the regulation of gene expression associated with the heart, blood vessels, viruses, inflammation, neurology, psychiatry, and developmental anomalies. Consequently, a comprehensive investigation of HOXA1-4 can offer valuable insights into the molecular biology of these diseases, thus providing potential research directions and targets for their development.

Role of HOA1-4 genes in the progression of cancer

The pivotal involvement of HOXA1-4 in the development and progression of diverse cancer types has been firmly established, as illustrated in Fig. 3. Numerous studies have consistently shown that the activation of HOXA1-4 genes can drive cancer progression. However, it is important to acknowledge that in certain tumor types, the impact of HOXA1-4 may exhibit an opposing effect, with their expression acting as a tumor suppressor.

Fig. 3

HOXA1-4 genes dysregulation in human cancers. The color code highlights alterations found for more than one HOXA gene in different tumor sites

Hepatocellular carcinoma (HCC)

Previous evidence has demonstrated that HOXA1 can serve as a methylation biomarker to improve sensitivity in the early-stage detection of HCC [58,59,60,61]. Meanwhile, numerous studies have indicated the regulation of HOXA1 and HOXA3 proteins by non-coding RNAs in HCC (Table 1). For instance, miR-218 and miR-99a directly bind to the putative 3'-UTR binding sites of HOXA1, inhibiting its expression levels and consequently suppressing the proliferation, invasion, and metastasis of HCC [62, 63]. Additionally, the H3K9 demethylase, KDM3A, is targeted by miRNA-202-3p and enhances expression of the HOXA1 by erasing the H3K9me2 to increase the growth of human HCC cell [64]. Moreover, the lncRNA HOXA-AS2 drives the malignant behavior of hepatoblastoma by upregulating HOXA3 expression [65]. Circular RNAs, as non-coding RNAs, also play a role in liver cancer progression. Knockdown of circWHSC1 has been shown to suppress the proliferation and metastasis of liver cancer cell lines by regulating HOXA1. Molecular studies have revealed that circWHSC1 functions as a sponge for miR-142-3p, which targets HOXA1 [66].

Table 1 HOXA1-4 genes were regulated by ncRNA in cancers

Lung cancer

Multi-database joint analysis has revealed the upregulation of HOXA1 expression in non-small cell lung cancer (NSCLC). These databases, namely Oncomine, Gene Expression Profiling Interactive Analysis, the Multi Experiment Matrix, and The Cancer Genome Atlas (TCGA), have provided supporting evidence [91]. In contrast, the TCGA database has shown that HOXA3 expression is decreased in NSCLC tissues, and this finding has been verified through RT-PCR assay in clinical samples [92]. Additionally, studies conducted by Tang and Gao et al. have demonstrated that HOXA4, similar to HOXA3, functions as a tumor suppressor in the progression of lung cancer [93, 94].

The identification of DNA hypermethylation at promoter CpG islands has emerged as a critical factor in lung cancer progression. Notably, HOXA1 has shown highly significant hypermethylation in lung cancer, which holds promise as a potential marker for early detection of LUAD [95]. The hypermethylation of HOXA1 may be regulated by H3K27me3 through HOTAIR, thereby contributing to the development of chemoresistance in small-cell lung cancer (SCLC) [77]. Aberrant methylation of HOXA1 has also been observed in preinvasive lesions, which are implicated in the early stages of pulmonary adenocarcinoma (ADC) development [96]. Similarly, hypermethylation of CpG sites in the HOXA3/HOXA4 region has been detected in lung cancer [97].

A growing body of evidence indicates that the dysregulation of non-coding RNAs (ncRNAs) in conjunction with HOXA plays a regulatory role in lung cancer progression. For instance, miR-577 directly targets HOXA1, and the functional effect of miR-577 on lung cancer cells is contingent upon HOXA1 [74]. Knockdown of oncogenic lncRNA LINC00958 leads to the inhibition of an oncogenic phenotype, which can be restored by HOXA1 overexpression in LUAD [83]. Furthermore, HOXA3 is regulated by LncRNA HOXA-AS3, an oncogene that enhances cisplatin resistance and promotes EMT [80]. The role of HOXA extends beyond tumor proliferation, migration, and invasion, as it also contributes to immune evasion in lung cancer. Studies have demonstrated notable associations between HOXA1 and immune cell infiltration as well as immune checkpoints. Knockdown of HOXA1 in LUAD cells enhances the CD8⁺ T cell response [98].

Breast cancer (BC)

In a study using RT-PCR assay to analyze HOX gene expression in human invasive ductal BC tissues and normal tissues, significant differences in expression were observed for 11 HOX genes (HOXA1, A2, A3, A5, A9, C11, D3, D4, D8, D9, and D10) between cancerous and normal tissues. Specifically, HOXA1, A2, and A3 showed lower expression in cancerous tissues compared to normal tissues [99]. The functional relevance of HOXA1 in BC was also confirmed by Magali Belpaire et al. [100]. Additionally, a downregulation of HOXA4 was observed in BC patients compared to non-cancerous tissues, which may be attributed to increased DNA methylation levels of HOXA4 [101].

Contrasting these findings, some research suggests that HOXA1 acts as an oncogene. Liu et al. demonstrated that both mRNA and protein levels of HOXA1 were increased in BC. High expression of HOXA1 was associated with poor prognosis and advanced clinicopathological features in BC patients. Inhibition of HOXA1 significantly suppressed cell progression by enhancing cell apoptosis and inducing cell cycle arrest in BC cells [102].

Moreover, the regulation of HOXA1 and HOXA3 by non-coding RNAs plays a role in modulating BC progression. Overexpression of circRASSF2 increased HOXA1 protein expression, leading to enhanced abilities of proliferation, clone formation, invasion, and metastasis in BC cells [90]. LncRNA SNHG acts as a sponge for miR-193a-5p, activating the expression of HOXA1 [84]. In the case of HOXA3, overexpression of miR-338-3p downregulates HOXA3 expression, whereas knockdown of miR-338-3p increases HOXA3 expression [88].

Prostate cancer

PCa is a significant disease primarily affecting men. Studies have demonstrated that HOXA1 overexpression promotes the growth, invasion, and metastasis of PCa. Conversely, suppression of HOXA1 results in high expression of E-cadherin and low expression of Snail and MMP-3 in PCa cells, indicating a potential role in inhibiting cancer progression [103]. Additionally, non-coding RNAs (ncRNAs) play crucial roles in PCa tumorigenesis. An oncogenic role of HOXA1 has been observed in PCa, as its expression can be enhanced by circ_0074032, which functions as a decoy for miR-198 [87]. Moreover, HOXA2 [104] and HOXA4 [105] have also been implicated in PCa progression. Specifically, HOXA2 has been found to display markedly increased expression in metastatic PCa tumors compared to normal tissue, and it is associated with shorter OS in patients.

Gastric cancer

GC ranks as the third most common cancer globally. Research has shown that HOXA1 exhibits high expression in GC cells, and its inhibition has been observed to reduce the expression of the cell cycle-related protein cyclin D1 [106]. Moreover, HOXA1 is among the 27 DNA methylation markers that display a higher frequency or level of methylation in GC tissues compared to non-neoplastic mucosae tissues [107]. However, a study investigating HOXA2 revealed lower expression of the HOXA2 gene in GC tumor samples than in normal samples [108]. Furthermore, HOXA3 has been identified as a target gene of miR-338-3p, and the upregulation of LINC00689 suppresses miR-338-3p, resulting in increased expression of HOXA3 in GC cells [82].

Ovarian cancer (OC)

Analysis of data from the TCGA database has revealed a correlation between the overexpression of HOXA1 and A4 and the advanced Federation of Gynecology and Obstetrics (FIGO) stage in epithelial ovarian cancer (EOC) [109]. Furthermore, miR-10a-5p has been found to inhibit the aggressive phenotypes of OC cells by suppressing the expression of HOXA1 [67]. Notably, the overexpression of HOXA4 is significantly associated with shorter progression-free survival in high-grade serous ovarian carcinoma patients [110]. Additionally, HOXA4 expression is elevated in invasive OC compared to noninvasive OC [111, 112].

Head and neck squamous cell carcinoma (HNSCC)

Based on bioinformatics analysis utilizing gene co-expression network analysis, evidence suggests a negative correlation between the expression levels of HOXA1 and the survival prognosis of the tumor, implying a significant role in HNSCC development [113]. Moreover, both Gene Set Variation Analysis (GSVA) and Gene Set Enrichment Analysis (GSEA) have successfully linked HOXA1 expression to tumor-associated signaling pathways and cell adhesion junction pathways [114]. These findings receive further support from He et al.'s research [115].

Oral cancer

Five genes, namely ASCL4, CELSR3, HIST1H3J, HOXA1, and ZFP42, have been identified as being upregulated in oral squamous cell carcinoma (OSCC). These genes are involved in various biological processes, including DNA replication, mismatch repair, and the NOTCH-related signaling pathway [116]. The overexpression of HOXA1 in OSCC has been found to be associated with a poor prognosis [117]. Furthermore, HOXA1, in conjunction with Ki67 as a proliferation marker, has been linked to the development of OSCC [118]. Additionally, the study reports an increase in HOXA2 expression during oral dysplasia but its subsequent repression in oral cancer progression [119].

Pancreatic ductal adenocarcinoma (PDAC)

In PDAC, a study employed a panel consisting of 13 methylated DNA markers (MDMs), namely AK055957, CD1D, CLEC11A, FER1L4, GH05J042948, GRIN2D, HOXA1, LRRC4, NTRK3, PRKCB, RYR2, SHISA9, and ZNF781, in conjunction with carbohydrate antigen 19–9 (CA19-9), to effectively detect PDAC [120]. Furthermore, upregulation of HOXA4 has been observed in PDAC patients with a more favorable prognosis [121].

Cervical cancer (CC)

HOXA1 is acknowledged as a tumor activator due to its well-established role in promoting proliferation, migration, invasion, and aerobic glycolysis. Notably, its enrichment in CC has been extensively documented [122,123,124]. Furthermore, miR-10b has been identified as a regulator of HOXA1, targeting its 3′-UTR region and effectively suppressing CC cell growth and invasion [68]. Additionally, circEIF4G2 [89] and LINC00152 [81] act as sponges for miR‑218 and miR-216b-5p, respectively, thereby contributing to the functional regulation of CC. HOXA1 is targeted by miR‑218 and miR-216b-5p and directly modulates the expression of ENO1 and PGK1, thus promoting glycolysis and inducing cancer progression [125]. Correspondingly, HOXA1 exhibits increased expression in early-stage CC compared to adjacent noncancerous tissue and is associated with an unfavorable prognosis [126].

Esophageal squamous cell carcinoma (ESCC)

The expression of HOXA1 has been found to be elevated in ESCC cells in comparison to normal cells. Interestingly, the impact of HOXA1 on esophageal carcinoma can be mitigated through the use of antisense oligodeoxynucleotides, which effectively suppress the invasion and metastasis of esophageal carcinoma cells by inhibiting the activation of the PI3K/AKT signaling pathway [127]. Moreover, circ_0058063 exerts its influence on HOXA1 expression by targeting miR-377-3p, ultimately enhancing the proliferation of esophageal cancer [86].

Glioblastoma (GBM)

HOXA1 plays a pivotal role as a tumor activator in promoting the proliferation, metastasis, and invasion of GBM [128]. This activation mechanism is mediated by the lncRNA-HOTAIRM1 through epigenetic modifications [78]. These findings were confirmed by Xia et al. in their study conducted on GBM stem cells [129]. In the investigation of HOXA3, it was observed that HOXA3 is upregulated in GBM patients and is associated with an unfavorable prognosis. Notably, HOXA3 transcriptionally activates aerobic glycolysis, thereby significantly accelerating tumor progression [130, 131]. Furthermore, HOXA4 has been identified as being upregulated in GBM and glioma cells, with its expression levels strongly correlating with a poor prognosis [132].

Nasopharyngeal carcinoma (NPC)

MiR-100 functions by downregulating the expression of HOXA1, thereby suppressing the growth of NPC cells [71]. By utilizing GEO and gene methylation profiling data, the investigation has identified the expression levels of HOXA4 in NPC. The findings reveal that HOXA4 is characterized by hypermethylation, leading to its reduced expression, and it plays a crucial role in NPC progression [133].

Other cancers

Feng et al. discovered the involvement of the DLX6-AS1/miR-193b-3p/HOXA1 axis in thyroid carcinoma (TC). Depletion of DLX6-AS1 suppresses TC cell growth and induces autophagy by upregulating miR-193b-3p and downregulating HOXA1 expression [76]. Notably, the methylation level of HOXA1 is significantly higher in Biliary intraepithelial neoplasia, a precancerous lesion of extrahepatic cholangiocarcinoma (EHC) [134]. Moreover, miR-218 overexpression effectively inhibits the development of myelodysplastic neoplasm (MDS) by regulating cell proliferation, colony formation, and apoptosis both in vitro and in vivo. Mechanistically, miR-218 appears to target HOXA1, which plays a key role in the pathogenesis of MDS [72]. Likewise, overexpression of HOXA1 has been demonstrated to promote tumor facilitative effects, including cell proliferation, metastasis, and invasion, in endometrial cancer (EC) [79]. Additionally, aberrant methylation of HOXA2 has identified it as a potential biomarker for colorectal cancer (CRC) [135, 136]. Several studies have reported that miR-338-3p inhibits the development of T-cell lymphoblastic lymphoma by directly targeting the oncogenic factor HOXA3 through binding to the 3'‑UTR region [73]. Additionally, miR-10b has been found to target HOXA3, leading to the inhibition of proliferation and invasion in ccRCC cells [69].

In conclusion, HOXA1 plays a significant role in the regulation of the development and progression of major cancers that have a substantial impact on human survival, including lung cancer, BC,CRC, GC, and liver cancer. Notably, HOXA1 expression is consistently upregulated in lung cancer, GC, and liver cancer. However, its precise role in BC remains unclear, as some studies suggest its function as an oncogene while others indicate otherwise. HOXA2 has received comparatively less research attention, with its expression being downregulated in BC and GC, and hypermethylation observed in CRC. Furthermore, HOXA3 is upregulated in liver cancer and GC, while it is downregulated in lung cancer. Similar to HOXA1, the role of HOXA3 in BC remains uncertain. Conversely, HOXA4 serves as a tumor suppressor gene in lung cancer and BC.

Compared to HOXA-4, HOXA1 has received substantial attention in the investigation of various other tumors. It serves as an oncogene in CC, EC, GBM, HNSCC, NPC, OC, PCa, and TC, mediating tumor proliferation, migration, invasion, and drug resistance. In contrast, HOXA2 exhibits high expression in PCa. HOXA3 displays overexpression in ccRCC, GBM, and T‑LBL. Moreover, HOXA4 acts as an oncogene in GBM regulation, while inhibiting the biological functions of NPC.

Role of HOXA-AS2/3 in disease regulation

Long non-coding RNA HOXA cluster antisense RNA 2 and 3 (HOXA-AS2/3) is situated within the HOXA gene cluster. Multiple investigations have consistently shown the participation of HOXA-AS2/3 in the advancement of diverse ailments.

HOXA-AS2 in diseases

In the study of diabetic nephropathy, the HOXA-AS2/miRNA-302b-3p/TIMP3 axis has been determined to protect against inflammatory response and inhibit proliferation in podocytes, thereby mitigating the progression of diabetic nephropathy [137]. Furthermore, HOXA-AS2 upregulates tipe2 expression by directly targeting miR-17-5p, thereby safeguarding lung tissue from chronic intermittent hypoxia injury [138]. HOXA-AS2 targets miRNA-877-3p, which is upregulated following injury in human aortic vascular smooth muscle cells (HA-VSMCs), leading to increased proliferation and metastasis while suppressing VSMC apoptosis [139]. Through high-throughput mRNA sequencing, Zhu et al. revealed that HOXA-AS2 can inhibit endothelial inflammation by suppressing the NF-κB signaling pathway [140]. Inhibition of HOXA-AS2 can alleviate the progression of epilepsy by regulating the miR-372-3p/STAT3 axis [141]. Additionally, the highly expressed HOXA-AS2 modulates microglial polarization by interacting with the PRC2 complex and epigenetically suppressing PGC-1α, thereby increasing neuroinflammation [142]. Furthermore, the decreased expression of HOXA-AS2 negatively regulates systemic lupus erythematosus through inactivating the ERK signaling pathway [143] (Table 2).

Table 2 Role of HOXA- AS2/3 in diseases

HOXA-AS3 in diseases

In the investigation of atherosclerosis, the expression of HOXA-AS3 is positively associated with inflammatory atherosclerosis and interacts with NF-κB to induce endothelial inflammation [145]. Chi et al. have discovered that upregulation of HOXA-AS3 significantly promotes the progression of atherosclerosis by modulating the miR-455-5p/p27 Kip1 axis [144]. Additionally, HOXA-AS3 enhances the development of pulmonary arterial hypertension through the modulation of the miR-675-3p/PDE5 axis [146] (Table 2).

Moreover, multiple studies have demonstrated the tumorigenic role of HOXA-AS2/3 in various cancers, including CRC, gallbladder carcinoma (GBC), GC, HCC, pancreatic cancer (PC), malignant glioma, and others.

HOXA-AS2 in cancers

In HCC, the downregulation of HOXA-AS2 inhibits cell proliferation and invasion, while promoting apoptosis. Conversely, high expression of HOXA-AS2 is associated with larger tumor size, advanced TNM stages, and shorter OS [147]. Similarly, in GC, HOXA-AS2 showed significant upregulation in cancerous tissues compared to noncancerous tissues [148]. Through its interaction with EZH2, HOXA-AS2 binds to the promoter region of PLK3, P21, and DDIT3, leading to their suppression via H3K27 trimethylation and contributing to the progression of GC [149]. Similar observations have been made in CRC [150]. Li et al. demonstrated that HOXA-AS2 is highly expressed in CRC tissues compared to normal tissues, and its expression can serve as a predictor of poor prognosis in CRC patients [151]. The association between HOXA-AS2 and EZH2 has also been confirmed in PC [152], OSCC [153], acute myeloid leukemia (AML) [154], and glioma [155]. Furthermore, the downregulation of HOXA-AS2 induces cell apoptosis, arrests the cell cycle in the G1 phase, and inhibits metastasis and invasion in GBC [156]. In glioma, HOXA-AS2 affects the expression of E2F8, E2F1, ATF3, and STAT1, promoting the proliferation of glioma stem cells (GSCs) and enhancing their aggressiveness [157]. In CC, HOXA-AS2 enhances proliferation and metastasis by activating the Notch signaling pathway [158]. Moreover, HOXA-AS2 enhances metastasis and invasion of NSCLC cells through the activation of IGF2 [159].

Accumulating evidence suggests that HOXA-AS2 acts as a miRNA sponge to facilitate tumor progression by regulating gene expression. For instance, in glioma, HOXA-AS2 interacts with miR-373 and miR-302a to modulate the expression of EGFR, KDM2A/JAG1, resulting in enhanced vasculogenic mimicry (VM) formation, cell viability, and metastasis [160], as well as immune tolerance [161]. Similarly, in GBM, HOXA-AS2 targets miR-2116-3p, miR-885-5p, and miR-302a-3p, thereby regulating the expression of SERPINA3, RBBP4, and IGF1, which influence GBM progression [162,163,164]. In PCa, HOXA-AS2 plays a role in the regulation of cell proliferation, migration, and EMT through the miR-885-5p/KDM5B and miR-509-3p/PBX3 axes [165, 166]. Furthermore, in OSCC, HOXA-AS2 promotes tumor progression by modulating CDK8 and SNX5, while suppressing miR-567 and miR-520c-3p, respectively [167, 168]. Moreover, HOXA-AS2 acts as a sponge for miR-520c-3p and miR-106a to regulate TGFBR2/RELA and SCN3A, respectively, thereby enhancing tumor progression in BC [169, 170]. Additionally, HOXA-AS2 is implicated in the development and progression of various other cancers, including CC [171], papillary thyroid cancer[172], type I endometrial carcinoma [173], NPC [174], osteosarcoma [175], NSCLC [176], bladder cancer (BCa) [177], and thoracic aortic aneurysm [178]. In these cases, HOXA-AS2 modulates different miRNA-related pathways, such as miR-509-3p/BTN3A1, miR-15a-5p/HOXA3, miRNA-302c-3p/ZFX, miR-519/HIF-1α/PD-L1, miR-124-3p/E2F3, miR-216a-5p, miR-125b/Smad2, and miR-520d-3p/KIAA1522/IGF2BP3, to promote tumor progression (Table 3 and Fig. 4).

Table 3 Role of HOXA- AS2 in tumor regulation

Fig. 4

Role of HOXA- AS2 in tumor regulation

HOXA-AS3 in cancers

Kyung Jin Eoh et al. demonstrated in their study on EOC that a high expression of HOXA-AS3 is associated with shorter OS, and overexpression of HOXA-AS3 enhances the proliferation and metastasis of EOC cells [179]. In PC, HOXA-AS3 targets miR-29c to promote the expression of CDK6, thereby stimulating the growth of PC cells [180]. Meanwhile, the HOXA-AS3/miR-455-5p/PD-L1 [181] and miR-29c/ BMP1 [182] axis are implicated in the progression of HCC, as high expression of HOXA-AS3 leads to increased proliferation, metastasis, and invasion in HCC. In CC, HOXA-AS3 drives disease progression by modulating the activity of miR-29a-3p [183]. Furthermore, HOXA-AS3 interacts with HOXA3 to promote cisplatin resistance in NSCLC [80]. Simultaneously, HOXA-AS3 elevates the expression of TEAD1 through its competing endogenous RNA activity on miR-1286, ultimately inducing the proliferation and migration of HUVECs and EMT in osteosarcoma [184]. Moreover, HOXA-AS3 exerts regulatory control over miRNA-related pathways, including miR-455-5p/Notch1, miR-4319/SPNS2, miR-455-5p/USP3, miR-29a-3p/LTβR/NF-κB, miR-218-5p/COL1A1/LPCAT1, to promote progression in BCa [185], CRC [186], GBM [187], GC [188], and OSCC [189] (Table 4 and Fig. 5).

Table 4 Role of HOXA- AS3 in tumor regulation

Fig. 5

Role of HOXA- AS3 in tumor regulation

These studies offer valuable insights into the involvement of HOXA-AS2/3 in the onset and progression of diverse diseases, thereby illuminating potential therapeutic targets and prognostic indicators.

HOXA1-4 genes downstream: target genes and pathway modulation in cancers

Target genes

As a transcription factor, HOXA is pivotal in driving disease progression by targeting both the promoter and enhancer regions of genes. It exerts regulatory effects by binding to specific DNA sequences within these regions, thereby influencing the expression of downstream genes and contributing to the development and progression of a wide range of diseases.

The expression of HOXA1 has been found to be correlated with the transformation of VSMCs into macrophage-like cells. Mechanistic investigations have revealed that inhibiting HOXA1 leads to the suppression of transcriptional activation of NF-κB p65 and KLF4, thereby participating in the pathological manifestations of VSMCs [190]. Simultaneously, HOXA2 binds to a long-range enhancer of Hmx1, thereby regulating its expression. Hmx1 serves as a crucial transcription factor in the development of both the eye and ear [191].

In the context of cancer research, upregulation of HOXA1 has been observed in BC. Increased expression of HOXA1 has been shown to promote cell proliferation and enhance metastasis by directly binding to the promoter region of SMAD3, thus regulating its transcription [192]. Furthermore, HOXA1 has the ability to facilitate the enrichment of H3K4me1 and H3K27ac in the enhancer region of MEIS3, resulting in enhanced expression of MEIS3. MEIS3, in turn, regulates 3-phosphoinositide-dependent protein kinase 1 associated with the PI3K/AKT signaling pathway, thereby promoting migration and invasion in HCC [64]. Recent research has also uncovered a connection between transcriptional regulators of glycolytic metabolism and GBM progression. Specifically, HOXA3 activates the lysine-specific demethylase KDM6A, which then binds to binding sites on glycolytic genes and removes the histone modification H3K27me3. This process triggers aerobic glycolysis, promoting GBM progression [130]. Additionally, HOXA4 binds to the promoter region of ARHGAP25, exerting regulatory control over its transcriptional activity and influencing the growth, invasion, and migration of lung cancer cells [193]. HOXA4 also binds to the promoter of miR-138, which inhibits proliferation and gefitinib resistance in NSCLC [93].

HOXAs as a signaling modulator

HOXAs play a role in regulating various signaling pathways, including the Wnt/β-catenin, JAK-STAT, and MEK/ERK pathways, among others, that are implicated in carcinogenesis and are crucial in multiple types of cancer (Fig. 6).

Fig. 6

HOXA1-4 is involved in signaling pathways. These include the Wnt/β-catenin, JAK-STAT, MEK/ERK, and PI3K-AKT pathways

Utilizing bioinformatics tools such as GSEA and the Chinese Glioma Genome Atlas (CGGA), an analysis was conducted to investigate the impact of HOXA2 on glioma progression. Results showed that HOXA2 is highly expressed in tumor tissues compared to normal tissues. Overexpression of HOXA2 contributes to the activation of the JAK-STAT signaling pathway, the cell-adhesion-molecules (CAMS) pathway, focal adhesion, the cytosolic DNA sensing pathway, and natural killer cell-mediated cytotoxicity [194]. Additionally, the role of the Wnt/β-catenin pathway, known to be significant in oncogenesis and tumor development, has been explored in relation to HOXA1. Han et al. reported that miR-100 targets HOXA1, leading to increased invasion and migration abilities of NSCLC cells through the Wnt/β‐catenin pathway [70]. Similarly, the long non-coding RNA ZFPM2-AS1 acts as a competing endogenous RNA for miR-515, positively interacting with HOXA1 to activate the Wnt/β-catenin signaling pathway, promoting the development of retinoblastoma [85]. Furthermore, evidence suggests that HOXA1, functioning as a tumor suppressor gene, participates in the regulation of chemoresistance in small cell lung cancer (SCLC) through the NF-KB signaling pathway [195]. In OC, miR-99a targets HOXA1 to suppress OC proliferation by affecting the AKT/mTOR pathway [75]. Another notable pathway involving HOXA3 is the EGFR pathway. HOXA-AS2 enhances HOXA3 expression, thus activating the EGFR/Ras/Raf/MEK/ERK signaling pathway. This leads to increased glucocorticoid resistance by promoting proliferation and suppressing apoptosis in acute lymphoblastic leukemia cell lines [196].

Cross-talk between HOXs

In various diseases, interactions and co-expression among HOXA family members have been demonstrated through bioinformatics data and in vitro and in vivo results. This network regulation of genes may contribute significantly to the development of diseases. For instance, in endometriosis, all members of the HOXA gene family (except for HOXA1) were significantly down-regulated in ectopic tissues compared to normal endometrium [30]. In tumors, analysis of TCGA data revealed that HOXA2, HOXA9, and HOXA10 are significant genes associated with PCa and are dysregulated in PCa, affecting the OS of PCa patients. Notably, the expression of HOXA2, HOXA9, and HOXA10 is related to immune infiltrates of immune cells [197]. Research conducted in KIRC indicated a significant increase in the expression of HOXA4 and HOXA13, while HOXA7 and HOXA11 were decreased. Furthermore, high expression of HOXA2, HOXA3, and HOXA13, along with low expression of HOXA7, is associated with poor OS in KIRC patients [198]. However, in laryngeal squamous cell cancer, expression of HOXA2 and HOXA4 was significantly downregulated, while HOXA7 and HOXA9-13 were upregulated [199]. Through the use of various public databases and bioinformatics analyses, it has been observed that 11 HOXAs (HOXA1, HOXA2, HOXA3, HOXA4, HOXA5, HOXA6, HOXA7, HOXA9, HOXA10, HOXA11, and HOXA13) show high expression in lower-grade glioma and GBM tissues [200]. Additionally, in early-stage CRC, high-frequency hypermethylation of HOXA2, HOXA5, and HOXA6 was identified as the main reason for their low expression in CRC [136].

In addition to co-expressions among members of the HOXA family, there are also co-expressions with other members of the HOX family. For instance, HOXA3 exhibited upregulation in ependymoma when combined with ARX, HOXA5, HOXA9, and HOXC6 [201]. Furthermore, mechanistic investigations have revealed that 2F1, HNF3α, KLF6, and SP3 have the ability to bind to promoter regions shared by all HOX genes, thereby regulating their expression collectively [202].

HOXA1-4 genes potentiate disease treatment

Sclerostin (Sost), a secreted glycoprotein encoded by the mouse gene, plays a significant role in bone remodeling. Antibody therapy targeting sclerostin has been approved for the treatment of osteoporosis. In aged mice on a Western diet, knockouts of the Sost gene have been found to prevent aortic valve stenosis. Interestingly, the enhanced expression of HOXA1 was identified in valve interstitial cells of mice with the Sost gene knockout [203]. In studies on mouse embryos treated with phenytoin sodium, a known risk factor for cleft palate, a high expression of HOXA2 was observed in craniofacial tissues [204]. Furthermore, dihydroartemisinin, an extract derived from Artemisia apiacea, has demonstrated the ability to inhibit the differentiation of mesenchymal stem cells through the modulation of Runx2 and Col10a1 regulation by Pax6/HOXA2 [205].

In the investigation of HOXA function in tumor treatment, findings have revealed that the methylation of HOXA1 can be induced by HOTAIR, resulting in chemoresistance in SCLC via activation of the NF-κB pathway [195]. This mechanism has also been observed in cisplatin resistance in LUAD. Furthermore, a joint analysis of various databases has identified HOXA1, along with five other genes (BATF3, FOXA2, IRF5, SIX1, and ZBTB38), as a model for cisplatin resistance [206]. The combination of methylated HOXA1, CA19-9, and SST has been utilized for the diagnosis of stage I PC [207]. Additionally, the long non-coding RNA CCAT1 functions as a sponge for miR-218 to enhance gefitinib resistance in NSCLC by modulating HOXA1 [208]. KDM3A undergoes tyrosine phosphorylation, which in turn regulates the expression of HOXA1 to promote the growth of tamoxifen-resistant BC [209]. Radiotherapy is a commonly used treatment method for cancer patients, and in this context, HOXA1 has been identified as an independent predictor of tumor progression, exhibiting a positive correlation with the expression of genes that enhance radiation resistance, including EGFR, CDK6, and CAV1 [115]. Furthermore, when comparing imatinib mesylate-resistant chronic myeloid leukemia patients, the promoter hypermethylation of the HOXA4 gene was significantly higher in those who did not respond well to treatment [210]. Epigenetic silencing of HOXA4 is also associated with decreased sensitivity of chronic lymphocytic leukemia cells to treatment with fludarabine, ibrutinib, and idelalisib [211].

The broad expression and notable prognostic significance of HOXA1-4 genes have been observed across various human cancers. Consequently, targeting HOXA genes represents an appealing strategy for drug discovery, and extensive efforts have been devoted to developing therapies that selectively target these genes.

Conclusion and prospective

In summary, HOXA1-4 genes play a crucial role in the regulation of various diseases and the progression of tumors. In common diseases, mutations, epigenetic modifications, and gene dysregulation are significant pathogenic factors contributing to conditions such as developmental defects in the head and face, cardiovascular diseases, viral infections, and neurological development, as well as inflammatory reactions. In cancer, HOXA1-4 genes can function as either oncogenes or tumor suppressors and interact with other members of the HOX family to regulate tumor proliferation, invasion, and metastasis through signaling pathways such as JAK-STAT, MEK/ERK, and Wnt/β-catenin. Additionally, HOXA-AS2/3 has been implicated in the progression of various diseases, including vascular disorders and inflammation. In cancer, HOXA-AS2/3 is frequently overexpressed in several types of cancer, such as CC, GBM, GC, NSCLC, and OSCC. The elevated expression of HOXA-AS2/3 is associated with poor prognosis, drug resistance, cancer metastasis, and lower survival rates. It primarily acts as a sponge for miRNAs, participating in the regulation of tumor development and progression. Furthermore, the expression of HOXA1-4 is also connected to chemoresistance and response to radiotherapy. Therefore, studying the mechanisms underlying the involvement of HOXA1-4 in diseases and tumors can establish a solid theoretical foundation for gene therapy. However, the application of HOXA1-4 in targeted therapy is currently in the preclinical or clinical trial stages, necessitating further research in this area.